Literature DB >> 25922812

Letter: economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients (diabetes metab j 2015;39:74-81).

Hannah Seok1.   

Abstract

Entities:  

Year:  2015        PMID： 25922812      PMCID： PMC4411549          DOI： 10.4093/dmj.2015.39.2.171

Source DB:  PubMed          Journal:  Diabetes Metab J        ISSN： 2233-6079            Impact factor:   5.376


× No keyword cloud information.
  5 in total

Review 1.  Safety of dipeptidyl peptidase 4 inhibitors: a perspective review.

Authors:  Thomas Karagiannis; Panagiota Boura; Apostolos Tsapas
Journal:  Ther Adv Drug Saf       Date:  2014-06

Review 2.  Beyond glycemic control: cardiovascular effects of incretin-based therapies.

Authors:  Franca S Angeli; Richard P Shannon
Journal:  Front Horm Res       Date:  2014-06-10       Impact factor: 2.606

Review 3.  The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Paweł Kawalec; Alicja Mikrut; Sylwia Łopuch
Journal:  Diabetes Metab Res Rev       Date:  2014-05       Impact factor: 4.876

4.  Understanding the cardiovascular effects of incretin.

Authors:  Ji Sung Yoon; Hyoung Woo Lee
Journal:  Diabetes Metab J       Date:  2011-10-31       Impact factor: 5.376

5.  Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients.

Authors:  Antoni Sicras-Mainar; Ruth Navarro-Artieda
Journal:  Diabetes Metab J       Date:  2015-02-16       Impact factor: 5.376
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.